{"result": "(\"entity\"<|>INSULINA REGULAR<|>ORGANIZATION<|>Insulina regular is a type of insulin that is transparent and consists of insulin-zinc crystals, used for managing blood glucose levels in diabetic patients.)\n##\n(\"entity\"<|>ANÁLOGOS DE INSULINA ULTRARRÁPIDOS<|>ORGANIZATION<|>Análogos de insulina ultrarrápidos are rapid-acting insulin analogs that have been recently marketed, designed to provide quicker absorption and better control of postprandial blood glucose levels.)\n##\n(\"entity\"<|>PIoglitazona<|>ORGANIZATION<|>Pioglitazona is a medication used to treat type 2 diabetes by improving insulin sensitivity and helping to control blood sugar levels.)\n##\n(\"relationship\"<|>INSULINA REGULAR<|>DIABETES MELLITUS TYPE 1<|>Insulina regular is used to manage blood sugar levels in patients with Diabetes Mellitus Type 1<|>8)\n##\n(\"relationship\"<|>INSULINA REGULAR<|>DIABETES MELLITUS TYPE 2<|>Insulina regular can also be used to control blood glucose levels in patients with Diabetes Mellitus Type 2<|>6)\n##\n(\"relationship\"<|>ANÁLOGOS DE INSULINA ULTRARRÁPIDOS<|>DIABETES MELLITUS TYPE 1<|>Análogos de insulina ultrarrápidos are used to manage blood sugar levels in patients with Diabetes Mellitus Type 1<|>8)\n##\n(\"relationship\"<|>ANÁLOGOS DE INSULINA ULTRARRÁPIDOS<|>DIABETES MELLITUS TYPE 2<|>Análogos de insulina ultrarrápidos can be used to help control blood glucose in patients with Diabetes Mellitus Type 2<|>6)\n##\n(\"relationship\"<|>PIoglitazona<|>DIABETES MELLITUS TYPE 2<|>Pioglitazona is a medication that helps manage blood sugar levels in patients with Diabetes Mellitus Type 2<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: posprandial de 1,5-2 h) y disminu-\n         B. La insulina no puede atravesar el endotelio para acceder a la circulación sanguínea                                           yen el riesgo de hipoglucemia tardía (antes de la siguiente ingesta). Además, la rapidez de\n             mientras no está en forma de dímero o de monómero.                                                                           acción de los AIAR permite una administración justo antes de la ingesta o incluso después,\n         C. En términos de perfil farmacocinético, la insulina lispro, la insulina aspart y la insulina                                   frente a la IRH que requiere idealmente una administración previa antes de las comidas\n             glulisina son similares.                                                                                                     para conseguir los mejores resultados.\n         D.  La insulina regular es una solución transparente de cristales de insulina-zinc.                                              Recientemente se han comercializado análogos de insulina ultrarrápidos (faster aspart) y\n                                                                                                                                          existen otros en desarrollo (lispro ultrarrápida, lispro biochaperona), los cuales presentan\n                                                                                                                                          un inicio de absorción de insulina aún más precoz y una mayor acción de insulina en las\n         COMENTARIO                                                                                                                       primeras 2 h, lo que se traduce en un mejor control precoz de la glucemia posprandial, y que\n         Los análogos de insulina de acción rápida (AIAR) intentan simular la respuesta insulinose-                                       podrían ofrecer ventajas en determinados grupos de pacientes.\n         cretora rápida, potente y de corta duración que ocurre tras la ingesta en los individuos no                                      Referencias:\n         diabéticos (tabla 8). Actualmente disponemos de los AIAR lispro, aspart y glulisina. Estruc-                                     • Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n         turalmente, la insulina lispro presenta una inversión de los aminoácidos lisina y prolina que\n         ocupan en la insulina regular humana (IRH) la posición B29 y B28, respectivamente. Esta\n         inversión se traduce en un cambio conformacional que dificulta la formación de dímeros y\n         hexámeros, incluso en presencia de zinc. En el caso de la insulina aspart, la sustitución de\n         prolina por ácido aspártico (con cargas negativas) en la posición B28 da lugar a una menor\n         tendencia, en presencia de zinc, a la agregación de las moléculas de insulina. Finalmente,\n         en la insulina glulisina, la sustitución de asparagina por lisina en la posición B3 y de lisina\n         por ácido glutámico en la posición B29 favorece la mayor formación de monómeros tras la\n\n\n\n124                                                                                                                                                                                                                                                                    125\n---\n                                                                                                                                                                                                                                     DIABETES           2\n\n\n\n     68  En relación con las complicaciones del tratamiento insulínico en la DM1, indique                                                  69  La utilización de infusión subcutánea continua de insulina (ISCI) en comparación\n         cuál de las siguientes afirmaciones es falsa:                                                                                         con las dosis múltiples de insulina (DMI):\n         A. Las hipoglucemias son más frecuentes al intensificar el tratamiento.                                                               A. Requiere una dosis mayor de insulina.\n         B. Los pacientes en tratamiento insulínico intensivo presentan menor ganancia de peso que                                             B. Consigue reducir el número de hipoglucemias en pacientes con DM2.\n             con el convencional.                                                                                                              C. Mejora la HbA1c en un 0,3-0,5% tanto en DM1 como DM2.\n         C. Una mejoría rápida del control glucémico al iniciar tratamiento intensivo puede causar un                                          D.  Se asocia a un empeoramiento de la percepción de la calidad de vida tanto en niños\n             empeoramiento transitorio de una retinopatía preexistente.                                                                            como en adultos.\n         D.  Debe evitarse la inyección de insulina en zonas de lipohipertrofia, dado que la absorción\n             de insulina puede ser errática.                                                                                                   COMENTARIO\n         COMENTARIO                                                                                                                            Dosis de insulina e infusión subcutánea continua de insulina (ISCI)\n         Los tres grupos farmacológicos para el tratamiento de la diabetes que conllevan ganancia                                              El cálculo de los requerimientos de insulina para la ISCI se realiza según la dosis total diaria\n         ponderal son los secretagogos (sulfonilureas, glinidas), la pioglitazona y el tratamiento con                                         previa del paciente. En general, estos suelen ser aproximadamente un 25-30% inferiores a\n         insulina.                                                                                                                             los del paciente en tratamiento con dosis múltiples de insulina (DMI).\n         La principal limitación para un adecuado control metabólico en pacientes en tratamiento                                               Comparación\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>INSULINA LISPRO<|>ORGANIZATION<|>Insulina lispro is a rapid-acting insulin analog used to control blood sugar levels in diabetic patients, designed to mimic the natural insulin response after meals.)\n##\n(\"entity\"<|>INSULINA ASPART<|>ORGANIZATION<|>Insulina aspart is another rapid-acting insulin analog that helps manage blood glucose levels, particularly effective when taken just before or after meals.)\n##\n(\"entity\"<|>INSULINA GLULISINA<|>ORGANIZATION<|>Insulina glulisina is a rapid-acting insulin analog that provides quick control of blood sugar levels, similar to other rapid-acting insulins.)\n##\n(\"entity\"<|>DIABETES MELLITUS TYPE 1<|>EVENT<|>Diabetes Mellitus Type 1 is a chronic condition where the pancreas produces little or no insulin, requiring patients to manage their blood sugar levels through insulin therapy.)\n##\n(\"entity\"<|>DIABETES MELLITUS TYPE 2<|>EVENT<|>Diabetes Mellitus Type 2 is a chronic condition that affects the way the body processes blood sugar (glucose), often managed with lifestyle changes and medication.)\n##\n(\"entity\"<|>ISCI<|>ORGANIZATION<|>Infusión Subcutánea Continua de Insulina (ISCI) is a method of delivering insulin continuously through a pump to maintain stable blood glucose levels in diabetic patients.)\n##\n(\"entity\"<|>DMI<|>ORGANIZATION<|>Dosis Múltiples de Insulina (DMI) refers to the traditional method of insulin administration where patients take multiple injections throughout the day to manage their diabetes.)\n##\n(\"relationship\"<|>INSULINA LISPRO<|>DIABETES MELLITUS TYPE 1<|>Insulina lispro is used to manage blood sugar levels in patients with Diabetes Mellitus Type 1<|>8)\n##\n(\"relationship\"<|>INSULINA ASPART<|>DIABETES MELLITUS TYPE 1<|>Insulina aspart is utilized for controlling blood glucose in individuals with Diabetes Mellitus Type 1<|>8)\n##\n(\"relationship\"<|>INSULINA GLULISINA<|>DIABETES MELLITUS TYPE 1<|>Insulina glulisina is administered to help manage blood sugar levels in patients with Diabetes Mellitus Type 1<|>8)\n##\n(\"relationship\"<|>ISCI<|>DIABETES MELLITUS TYPE 1<|>ISCI is a treatment option for patients with Diabetes Mellitus Type 1 to maintain stable blood glucose levels<|>7)\n##\n(\"relationship\"<|>DMI<|>DIABETES MELLITUS TYPE 1<|>DMI is a common treatment method for managing Diabetes Mellitus Type 1 through multiple insulin injections<|>7)\n##\n(\"relationship\"<|>INSULINA LISPRO<|>DIABETES MELLITUS TYPE 2<|>Insulina lispro can also be used to manage blood sugar levels in patients with Diabetes Mellitus Type 2<|>6)\n##\n(\"relationship\"<|>INSULINA ASPART<|>DIABETES MELLITUS TYPE 2<|>Insulina aspart is effective for controlling blood glucose in individuals with Diabetes Mellitus Type 2<|>6)\n##\n(\"relationship\"<|>INSULINA GLULISINA<|>DIABETES MELLITUS TYPE 2<|>Insulina glulisina is used to help manage blood sugar levels in patients with Diabetes Mellitus Type 2<|>6)\n##\n(\"relationship\"<|>ISCI<|>DIABETES MELLITUS TYPE 2<|>ISCI is a treatment method for maintaining stable blood glucose levels in patients with Diabetes Mellitus Type 2<|>5)\n##\n(\"relationship\"<|>DMI<|>DIABETES MELLITUS TYPE 2<|>DMI is a traditional method for managing Diabetes Mellitus Type 2 through multiple insulin injections<|>5)\n<|COMPLETE|>"}]}